On August 21, 2026, in Beijing, a significant advancement was achieved in personalized mRNA cancer therapy. A Phase 3 study conducted internationally for high-risk melanoma displayed encouraging outcomes, reinforcing the efficacy of personalized neoantigen therapy. This milestone signifies a crucial step forward in the field of cancer treatment.